Table 2.
Baseline clinical and immunological profile of HIV positive children on ART in Amhara Regional State referral hospitals, Ethiopia from the 1st of January, 2012 – the 28th February, 2017
| Variables | Frequency (N) | Percentage (%) |
|---|---|---|
| OI at baseline | ||
| Yes | 182 | 53.3 |
| No | 208 | 46.7 |
| Functional status (age ≥5 year) (N = 262) | ||
| Working | 150 | 57.3 |
| Ambulatory | 105 | 40.1 |
| Bedridden | 7 | 2.7 |
| Developmental History (age < 5 years) (N = 128) | ||
| Appropriate | 97 | 75.8 |
| Delayed | 24 | 17.8 |
| Regressive | 7 | 5.5 |
| WHO clinical stage | ||
| Stage I and II | 229 | 58.8 |
| Stage III and IV | 161 | 41.2 |
| Past TB test before ART | ||
| Not determined | 310 | 79.5 |
| Negative | 37 | 9.5 |
| Positive | 43 | 11.0 |
| Past TB treatment | ||
| No treatment | 346 | 88.7 |
| 2SRHZ/4RH | 30 | 7.7 |
| 2HRZES/4HRE | 3 | 0.8 |
| HRZE/4RH | 11 | 2.8 |
| CD4 count or percent | ||
| Below the threshold | 273 | 70.0 |
| Above the threshold | 117 | 30.0 |
| Hemoglobin level | ||
| < 10 g/dl | 47 | 12.0 |
| ≥10 g/dl | 343 | 88.0 |
| ART eligibility criteria | ||
| Immunologic/ CD4 | 107 | 27.9 |
| WHO clinical stage | 47 | 12.0 |
| Both clinical and immunologic | 152 | 39.0 |
| Without criteria | 84 | 21.5 |
| Type of Regimen during follow up | ||
| 4a = d4t-3TC-NVP | 48 | 12.3 |
| 4b = d4t-3TC-EFV | 22 | 5.6 |
| 4c = AZT-3TC-NVP | 149 | 38.2 |
| 4d = AZT-3TC-EFV | 78 | 20.0 |
| 1e = TDF-3TC-EFV | 35 | 9.0 |
| 1 h = ABC-3TC-NVP | 10 | 2.6 |
| 1 g = ABC-3TC-EFV | 13 | 3.3 |
| 2nd line | 9 | 2.3 |
| Others | 26 | 6.7 |
| OI during follow-up | ||
| Yes | 107 | 27.4 |
| No | 283 | 72.6 |
| Cotrimoxazole preventive therapy | ||
| Yes | 233 | 59.7 |
| No | 157 | 40.3 |
| Regimen change during follow-up | ||
| Yes | 118 | 30.3 |
| No | 272 | 69.7 |
| Regimen stopped during follow-up | ||
| Yes | 18 | 4.6 |
| No | 372 | 95.4 |
| ART adherence in the 1st 3 months | ||
| Good /fair | 495 | 92.2 |
| Poor | 42 | 7.8 |